{
    "clinical_study": {
        "@rank": "114461", 
        "arm_group": [
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Rifampin plus rosuvastatin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The effect of transporter inhibition by rifampin on the pharmacokinetics of rosuvastatin\n      will be studied in clinical trial in White and Asian healthy volunteers."
        }, 
        "brief_title": "The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Asian volunteers of Han-Chinese/Japanese/Korean descent whose parents and\n             grandparents are Han-Chinese/ Japanese/ Korean.\n\n          -  Healthy Caucasian volunteers of White/Caucasian/European-born descent whose parents\n             and grandparents are White/Caucasian/European.\n\n          -  Male or female, ages 18-65 years old, with no current medical conditions or active\n             diagnoses as determined by the study doctor based on history, physical exam, and\n             laboratory evaluations.\n\n          -  Subjects who take no other medications two weeks prior to the study and during the\n             time course of the study including prescription medications, over-the-counter\n             medications, dietary supplements, or drugs of abuse.\n\n          -  Subjects with the following genotype: SLCO1B1*1a and ABCG2 421CC.\n\n          -  Subjects able to maintain adequate birth control during the study independent of\n             hormonal contraceptive use.\n\n          -  Subjects able to abstain from grapefruit, grapefruit juice, oranges, orange juice,\n             caffeinated beverages and/or alcoholic beverages from 7am the day before the study to\n             completion of that study day.\n\n          -  Participants determined to have normal liver and kidney function as measured at\n             baseline\n\n          -  BMI between 18.0 - 30 kg/m2\n\n          -  Subjects capable of fasting from food and beverages at least 8 hours prior to\n             medication dosing.\n\n          -  Be able to read, speak, and understand English.\n\n          -  Subjects capable of providing informed consent and completing the requirements of the\n             study.\n\n        Exclusion Criteria:\n\n          -  Subjects with active medical problems\n\n          -  Subjects on chronic prescription or OTC medication that cannot be stopped 2 weeks\n             prior to and during the study.\n\n          -  Subjects incapable of multiple blood draws (HCT < 30mg/dL)\n\n          -  Subjects with a history of rhabdomyolysis\n\n          -  Subjects with a history of drug-related myalgias\n\n          -  Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias\n\n          -  Subjects with a history of GI bleed or peptic ulcer disease\n\n          -  Subjects who smoke tobacco or have ongoing alcohol or illegal drug use\n\n          -  Subjects who are pregnant, lactating, or trying to conceive during the study period\n\n          -  Subjects allergic to rosuvastatin or rifampin or any known component of the\n             medications\n\n          -  Anyone who in the opinion of the study investigators is unable to do the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106767", 
            "org_study_id": "14-12970"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rosuvastatin", 
                "description": "Rosuvastatin 20mg po x1", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Crestor"
            }, 
            {
                "arm_group_label": "Rifampin plus rosuvastatin", 
                "description": "Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1", 
                "intervention_name": "Rosuvastatin plus rifampin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Crestor", 
                    "Rifadin", 
                    "Rifampicin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rifampin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rosuvastatin", 
            "rifampin", 
            "pharmacokinetics", 
            "drug interaction", 
            "healthy volunteer", 
            "drug transporter", 
            "Asian", 
            "White"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "nadya.hristeva@ucsf.edu", 
                "last_name": "Nadya Hristeva, BS", 
                "phone": "415-476-5890"
            }, 
            "contact_backup": {
                "email": "frassett@gcrc.ucsf.edu", 
                "last_name": "Lynda Frassetto, M.D.", 
                "phone": "415-476-6143"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94143"
                }, 
                "name": "CTSI Clinical Research Center, UCSF"
            }, 
            "investigator": [
                {
                    "last_name": "Leslie Z Benet, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Lynda Frassetto, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Single-Dose Rifampin on the Pharmacokinetics of Rosuvastatin in Healthy White and Asian Volunteers", 
        "overall_contact": {
            "email": "nadya.hristeva@ucsf.edu", 
            "last_name": "Nadya Hristeva, BS", 
            "phone": "415-476-5890"
        }, 
        "overall_contact_backup": {
            "email": "frassett@gcrc.ucsf.edu", 
            "last_name": "Lynda Frassetto, M.D.", 
            "phone": "415-476-6143"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Leslie Z Benet, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Lynda Frassetto, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area-under-the-concentration curve (AUC) of rosuvastatin", 
            "safety_issue": "No", 
            "time_frame": "Blood samples collected over a 48 hour period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106767"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum plasma concentration (Cmax) of rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 32, and 48 hours post-dose"
            }, 
            {
                "measure": "Time to concentration maximum (Tmax) of rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 32, and 48 hours post-dose"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}